These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23026590)

  • 1. Sirolimus in renal transplantation: analysis of safety and efficacy in a nonprotocol conversion group.
    Gois PH; Rivelli GG; Pereira LM; Mazzali M
    Transplant Proc; 2012 Oct; 44(8):2348-51. PubMed ID: 23026590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM; Sahin S; Kantarci G; Ergin H
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Gonzalez Molina M; Hernandez D
    Transplant Proc; 2009; 41(6):2137-8. PubMed ID: 19715855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
    Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
    Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.